STA
DOVA

Summit Trail Advisors’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Summit Trail Advisors’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-7
Closed – – 1989
2017
Q4 		$0 Buy
+7
New +$192 ﹤0.01% 2155

Other funds holding DOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return

Summit Trail Advisors's DOVA Position: Q1 2018 in Review

Summit Trail Advisors sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q1 2018, closing a stake of 7 shares.

Summit Trail Advisors first reported a position in DOVA in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 55 funds tracked by Wall St. Rank hold DOVA as of Q1 2018.

  • Summit Trail Advisors reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 7 Dova Pharmaceuticals, Inc. Common Stock shares in Q1 2018.
  • Summit Trail Advisors first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Summit Trail Advisors's Dova Pharmaceuticals, Inc. Common Stock position peaked at $0 in Q4 2017.
  • 55 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.